Enveric Biosciences
ENVB
18 hedge funds and large institutions have $4.64M invested in Enveric Biosciences in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.
579% more call options, than puts
Call options by funds: $740K | Put options by funds: $109K
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
71% more capital invested
Capital invested by funds: $2.72M → $4.64M (+$1.92M)
29% more funds holding
Funds holding: 14 → 18 (+4)
5.09% more ownership
Funds ownership: 5.37% → 10.46% (+5.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.07M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$680K |
| 3 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
+$194K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$175K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$136K |
| 2 |
PCM
Penserra Capital Management
Orinda,
California
|
-$52K |
| 3 |
BlackRock
New York
|
-$19.4K |
| 4 |
S
SignatureFD
Atlanta,
Georgia
|
-$19.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$19.4K |
ENVB Hedge Fund Activity: Q3 2021 in Review
18 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q3 2021, worth a combined $4.64M — up 71% from $2.72M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ENVB positions and 5 closed out — a net gain of 4 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.07M. The largest seller was UBS Group, exiting entirely with an estimated $136K sold.
- 18 institutional investors held Enveric Biosciences (ENVB) as of Q3 2021, up from 14 in Q2 2021.
- Funds reported $4.64M of Enveric Biosciences stock for Q3 2021, up 71% quarter-over-quarter.
- 9 funds opened new Enveric Biosciences positions in Q3 2021 and 5 closed out, a net change of +4 holders.
- The largest Enveric Biosciences buyer in Q3 2021 was Renaissance Technologies, an estimated $1.07M added.
- The largest Enveric Biosciences seller in Q3 2021 was UBS Group, an estimated $136K sold.
Based on aggregated 13F filings for Q3 2021.